Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Kymriah
Kymriah
For CAR-T Cancer Fighters in the Real World, Two Roads Diverge
Xconomy
Thu, 01/3/19 - 04:16 pm
cancer
CAR-T
Gilead Sciences
Yescarta
Novartis
Kymriah
Novartis seeks to acquire French CAR-T contract manufacturer
Biopharma Dive
Thu, 12/20/18 - 11:43 pm
Novartis
M&A
France
CellforCure
CMO
Kymriah
CAR-T
Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask
Fierce Pharma
Tue, 12/18/18 - 12:51 pm
Novartis
patients
CAR-T
Kymriah
drug manufacturing
2 Sets of Disasters Biotech Will Pay For in 2019
Yahoo/Motley Fool
Mon, 12/17/18 - 12:16 am
Gilead Sciences
Yescarta
Novartis
Kymriah
Spark Therapeutics
Luxturna
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah
Fierce Pharma
Sun, 12/2/18 - 11:01 pm
Gilead
Novartis
CAR-T
Yescarta
Kymriah
ASH2018
Novartis’ CAR-T cancer drug available on NHS to young people
Pharmaforum
Sat, 11/17/18 - 12:34 pm
Novartis
CAR-T
NHS
refractory B-cell acute lymphoblastic leukemia
Kymriah
Insight: How Novartis built a ‘money-filled moat’ to market Kymriah
Biopharma Reporter
Thu, 10/4/18 - 06:59 pm
Novartis
Kymriah
competition
drug marketing
CAR-T
Novartis signs manufacturing deal for Kymriah in China
BioCentury
Thu, 09/27/18 - 11:00 pm
Novartis
Kymriah
China
drug manufacturing
NICE rejects Novartis’ CAR-T in adult lymphoma
Pharmaforum
Wed, 09/19/18 - 11:22 pm
NICE
UK
Novartis
CAR-T
Kymriah
NHS
diffuse large B-cell lymphoma
Novartis CAR-T therapy snags UK coverage, cutting list price 23% from US
Biopharma Dive
Wed, 09/5/18 - 10:01 pm
Novartis
Kymriah
CAR-T
UK
Novartis announces new €78m plant and 450 new jobs to manufacture Kymriah in EU
GoinPharma
Tue, 08/28/18 - 07:58 pm
Novartis
Europe
Kymriah
ALL
acute lymphoblastic leukemia
Novartis wins a key OK for Kymriah, but continuing manufacturing woes hobble rollout — rival Gilead CAR-T breaks into Europe
Endpoints
Mon, 08/27/18 - 10:10 am
Novartis
CAR-T
Kymriah
drug manufacturing
Kymriah Manufacturing Issues Spell Trouble for Commercialization of Novartis CAR-T Therapy
Xtalks
Mon, 07/23/18 - 10:40 pm
Novartis
Kymriah
drug manufacturing
CAR-T
Cell for Cure
Could an old Amgen-developed RA drug make CAR-T treatments safer?
Fierce Biotech
Thu, 06/7/18 - 10:08 am
CAR-T
cytokine release syndrome
Kymriah
Yescarta
Amgen
Kineret
New approval sets up CAR-T showdown for Gilead, Novartis
Biopharma Dive
Wed, 05/2/18 - 10:00 pm
Kymriah
Novartis
cell therapy
Yescarta
Gilead Sciences
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
Tue, 02/20/18 - 09:58 am
CAR-T
ICER
Gilead Sciences
Yescarta
Novartis
Kymriah
drug pricing
Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US
Market Realist
Mon, 02/19/18 - 09:48 am
Novartis
Kymriah
gene therapy
acute lymphoblastic leukemia
Novartis could cut its Kymriah price to $160,000 and keep its profit margins: study
Fierce Pharma
Thu, 02/8/18 - 11:55 pm
Novartis
Kymriah
pricing
Patient Advocate Says Novartis' $475,000 Breakthrough Should Cost Just $160,000
Forbes
Thu, 02/8/18 - 11:47 pm
Novartis
drug pricing
Kymriah
Top 10 stories that had pharma execs talking
Biopharma Dive
Thu, 01/4/18 - 12:02 pm
M&A
Bristol-Myers Squibb
Opdivo
Express Scripts
Novartis
C-ART
Kymriah
Massachusetts
AbbVie
Kenneth Frazier
biosimilars
CVS Health Pfizer
Pages
« first
‹ previous
1
2
3
next ›
last »